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Severe LAD-I (predominantly classified as <2% of CD18-expressing neutrophils) is characterized by recurrent, lifethreatening bacterial and other infections and substantial infant mortality in patients who do not receive allogeneic hematopoietic stem cell transplant (HSCT). Mortality for severe LAD-I was reported as 75% by the age of 2 years in an initial 1988 multicenter retrospective evaluation. 3 Most patients with moderate LAD-I (2%-30% CD18-expressing neutrophils) survive childhood, with recurrent infections of skin and mucosal surfaces; mortality by the age of 40 years reportedly exceeds 50%. 3 LAD-I is also characterized by umbilical cord complications (delayed separation and omphalitis), impaired wound healing, and persistent leukocytosis. 4, 5 Multiple reports have been published in recent decades; however, no comprehensive prognostic assessments are available subsequent to the 1988 report. We sought an updated understanding of severe LAD-I with emphasis on prognosis in the absence of HSCT, HSCT outcomes, and association of CD18 expression with clinical features. We created a database of all published LAD-I cases via PubMed searches and a review of additional references.
Three hundred twenty-three LAD-I cases were reported between 1975 and 2017 in 107 publications (68 of which were single case reports; largest series n ¼ 36). The nations with the highest number of cases were Iran (n ¼ 65), the United States (n ¼ 50), and India (n ¼ 45); the highest number of publications originated in the United States (n ¼ 25) (see Table E1 in this article's Online Repository at www.jaci-inpractice.org for a comprehensive listing of publications and patient numbers by country and Table E2 for a comprehensive listing of references).
Per investigator assessment, 113 patients were considered to have severe LAD-I, 63 moderate, and 147 not classified. Neutrophil CD18 expression was reported for 265 cases and was less than 2% in 135 patients (51%) and 2% or more in 130 patients (49%). Four patients with CD18 greater than or equal to 2% were considered to have severe LAD-I (CD18% range, 2.4-17.3). Sex information was available for 282 patients, of which 148 (52%) were males.
Age at presentation was reported for 146 cases. For 63 patients with CD18 less than 2%, median presentation was at age 1 month (range, 0.03-18 months); for 62 patients with CD18 of 2% or more, median presentation was at age 6 months (range, 0.03-192 months). HSCT was performed for 125 patients; 198 patients did not undergo HSCT.
Infections were described for 248 (77%) of the 323 cases; information regarding anatomic site and CD18% was specified in 154 cases (48%). The most frequent infections in 85 cases with CD18 less than 2% were respiratory tract (39%, including pneumonia), sepsis (29%), and otitis media (27%). The most frequent infections in 69 cases with CD18 of 2% or more were periodontal (52%, including gingivitis and oral ulcers), otitis media (36%), and sepsis (25%). Perianal skin infections and necrotic skin ulcers were each reported in more than 10% of the groups. For additional information, see Table E3 in this article's Online Repository at www.jaci-inpractice.org.
Umbilical cord complications (delayed separation or omphalitis) were more frequent in patients with severe LAD-I, reported in 92 of 110 patients with CD18 less than 2% (84%) and 47 of 81 patients with CD18 of 2% or more (58%; P ¼ .0001; c 2 test). For the subset of patients with severe LAD-I with at least 2 years of follow-up (or death before the age of 2 years), there was significant correlation between absence of umbilical cord complications and survival to 24 months (P < .001; Fisher exact test). Tables E4 and E5 in this article's Online Repository at www.jaci-inpractice.org depict umbilical cord complication incidences and 2-year survival.
White blood cell (WBC) counts were reported in 143 cases (median, 45 Â 10 9 /L; range, 10-150 Â 10 9 /L). Although median WBC was higher in the group with CD18 less than 2% (48 vs 30 Â 10 9 /L), there was limited correlation between CD18 expression and WBC (r < 0.1) for the entire cohort and when the groups with CD18 less than 2% and of 2% or more were analyzed independently. Expression of b 2 -integrin heterodimers CD11a, CD11b, and CD11c was reported in 76, 89, and 69 cases, respectively. Correlations between CD18 and CD11 expressions were also limited (r < 0.5), consistent with a recent report. 6 Figures E1 and E2 in this article's Online Repository at www.jaci-inpractice.org depict analyses regarding integrin expression and WBC.
Mutation analyses were provided for 139 cases; missense (n ¼ 34) and frame shift (n ¼ 24) mutations were most frequent for the subset (n ¼ 100) in which these were characterized. More than 20 locations within the ITGB2 gene were specified (n ¼ 120); however, mutations on Exon 6 were most frequent (24%) and mutations on Exons 5, 6, and 7 accounted for 44% of specified cases. We also identified 18 cases in which CD18 expression was more than 30% (range, 31%-99%). In 8 of 12 cases in which CD18 was more than 30% and CD11 information was available, at least 1 CD11 moiety was reported as less than 2%, consistent with recent descriptions of mutations enabling surface expression of nonfunctional CD18. 6 Clinical and genetic details of these cases are provided in Table E6 of this article's Online Repository at www.jaci-inpractice.org.
We sought to understand whether prognosis for severe LAD-I in the absence of HSCT is similar to the initially reported 25% survival to the age of 2 years. There were 66 severe LAD-I cases (per investigator assessment or CD18 less than 2%) for whom survival to 2 years was reported, 40 of whom died before the age of 2 years (61% mortality). As indicated in Table I , survival to the age of 2 years was similar for severe LAD-I subsets defined strictly by CD18 expression, and for severe cases reported since 2000. One patient with severe LAD-I survived beyond the age of 12 years (death at 13.5 years). Because many reports did not provide precise survival durations for severe LAD-I (stating only that mortality occurred before the age of 2 years), it was not possible to generate Kaplan-Meier plots incorporating most of the severe LAD-I cases. Survival to the age of 2 years and throughout early childhood exceeded 90% for patients with more than 4% CD18 expression. Figure 1 shows the survival probability for LAD-I cases on the basis of CD18 expression.
Outcomes for 101 patients receiving HSCT were consistent with recent series. 7, 8 Phenotypic correction was reported in 83% of HLA-identical sibling allograft recipients. Transplant-related mortality was 19% across all groups (11% for HLA-matched sibling recipients). Seven of 22 (32%) haploidentical recipients had HSCT-related mortality and 12 (55%) received at least 1 Many reports did not provide precise survival durations (stating only that mortality occurred before the age of 2 y), and hence it was not possible to generate Kaplan-Meier curves incorporating most of the severe LAD-I cases. Several patients were considered to have severe LAD-I despite CD18 expression on >2% neutrophils or unspecified CD18 expression; these cases are included in the top row in addition to those with CD18 expression on <2% neutrophils. FIGURE 1. Kaplan-Meier survival estimates for patients with moderate LAD-I not receiving allogeneic HSCT, by CD18 expression. Because many reports did not provide precise survival (stating only that mortality occurred before the age of 2 years), it was not possible to generate plots incorporating most of the severe cases. The gray diamond indicates the 39% survival to the age of 2 years for 66 evaluable patients with severe LAD-I not receiving HSCT.
subsequent transplant. HSCT outcomes were not markedly different for cases in publications before 2000 (n ¼ 23) versus those from 2000 to 2017 (n ¼ 78), although the more recent interval included matched unrelated donor (n ¼ 24) and cord blood (n ¼ 6) transplants. Additional transplant information is provided in Table E7 in this article's Online Repository at www.jaci-inpractice.org.
Our findings indicate that severe LAD-I remains a lifethreatening condition with limited 2-year survival in the absence of allogeneic HSCT. Potential publication biases may include predilection for reporting more severe cases and those with favorable treatment outcomes; there is also potential underreporting from regions with higher disease incidence, in which LAD-I management is a component of regular practice. Umbilical cord complications and granulocytosis are frequent early LAD-I manifestations. Respiratory tract, ear, sepsis, oral, and skin infections are common. HSCT is the only available curative therapy; transplant-related mortality and other complications occur frequently, especially in haploidentical transplants. In addition to flow cytometry, genetic evaluation may confer meaningful diagnostic and prognostic information. Rapid identification of patients with potential LAD-I (unusual or severe infections during infancy, granulocytosis, and umbilical cord complications) is essential to enable referral to centers with disease expertise and early implementation of definitive therapy. Umbilical cord complications include delayed cord separation and omphalitis. Table includes information for 42 patients from whom information regarding umbilical cord complications was available, and for whom follow-up to age 2 y (or death before the age 2 of y) was provided. 
